news
Phase I/II trial initiated to study VLA2001, potential COVID-19 vaccine
Valneva has initiated its Phase I/II trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
List view / Grid view
UK National Institute for Health Research (NIHR)
Filter the results
news
UK leads Europe in Phase I and Phase II trials, ABPI findings show
The ABPI has found that the UK is leading the rest of Europe in early-stage clinical trials and makes suggestions on how the country can maintain this position.
news
Further £8.4 million in funding given to UK researchers studying immune response to COVID-19
The funding is being split across three research projects that will hopefully improve the treatment of COVID-19 and inform the development of vaccines and therapeutics.
news
UKRI announces six research initiatives into COVID-19 and ethnicity
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
news
Experimental motor neurone disease therapy shows promise
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.
news
UK national priority COVID-19 trial now recruiting patients
The PRINCIPLE trial aims to evaluate therapeutics that could slow the progression of COVID-19 symptoms in patients most at risk of complications.
news
Positive results from initial lopinavir-ritonavir COVID-19 clinical trial
Researchers found that the combination of lopinavir-ritonavir HIV antivirals led to rapid symptom improvement in COVID-19 patients.
news
Dr William van’t Hoff next NIHR Clinical Research Network Chief Executive
The next Chief Executive of the National Institute for Health Research’s Clinical Research Network has been announced as Dr William van’t Hoff.